Global Acetaminophen Industry to 2031

company logo

Dublin, May 30, 2022 (GLOBE NEWSWIRE) — The “Acetaminophen Market” report has been added to from ResearchAndMarkets.com offer.

This Acetaminophen market report offers overall industry analysis for 2016-2020 and opportunity assessment for 2021-2031.

The report consists of a comprehensive assessment of the most important market dynamics. By conducting extensive research on the historical and current growth parameters of the Acetaminophen market, market growth prospects are obtained with utmost accuracy.

The report presents unique and salient factors which may have a huge impact on the development of the Acetaminophen market during the forecast period.

It can help market players to modify their manufacturing and marketing strategies to envision maximum growth of this market in the coming years.

The report provides detailed information about the current and future growth prospects of the Acetaminophen market in the most comprehensive manner for the better understanding of the readers.

Main topics covered:

1. Summary

2. Market Overview
2.1. Market coverage/taxonomy
2.2. Market Definition/Scope/Limitations
2.3. Inclusions and exclusions

3. Key Market Trends
3.1. Key trends impacting the market
3.2. Innovation/Product Development Trends

4. Key success factors
4.1. Key Strategies Adopted by Manufacturers
4.2. Regulatory scenario
4.3. Pipeline analysis
4.4. Disease epidemiology

5. Market Context
5.1. Macroeconomic factors
5.1.1. Global GDP Growth Prospects
5.1.2. Global Health Outlook
5.1.3. Prospects for health expenditure per capita
5.2. Predictors – Relevance and Impact
5.2.1. Average annual spending on pain medication
5.2.2. Average health expenditure
5.2.3. Increase in the prevalence of chronic and acute diseases
5.2.4. Growing number of patients undergoing surgeries
5.2.5. Increase in the number of people with terminal illnesses
5.2.6. Pharmaceutical expenditure per capita
5.2.7. Pain Management Medication Awareness
5.2.8. Favorable refund policies
5.2.9. Regulatory control of the prescription
5.2.10. Popularity of generic products
5.2.11. Patent expiration of new drugs for pain management (opioids)
5.2.12. Introducing New Anti-Abuse Pain Medications
5.3. Market dynamics
5.3.1. Drivers
5.3.2. Constraints
5.3.3. Opportunity analysis

6. COVID19 crisis analysis
6.1. Current likely future impact of COVID19
6.2. Current GDP projection and likely impact
6.3. Current economic projection compared to 2008 Economic analysis
6.4. COVID19 and impact analysis
6.4.1.1. Turnover by product
6.4.1.2. Turnover by type of sale
6.4.1.3. Recipes by route of administration
6.4.1.4. Revenue by distribution channel
6.4.1.5. Revenue by country
6.5. Market scenario 2020

7. Global Acetaminophen Market Demand Analysis (by value or size in USD Million) 2016-2020 and Forecast, 2021-2031
7.1. Historical Market Value Analysis (USD Million), 2016-2020
7.2. Current and Future Market Value Projections (USD Million), 2021-2031
7.2.1. Analysis of annual growth trends
7.2.2. Analysis of opportunities in absolute dollars

8. Global Acetaminophen Market Analysis 2016-2020 and Forecast 2021-2031, by Product
8.1. Introduction/Key Findings
8.2. Historical Trend Analysis of Market Size (USD Million) by Product, 2016-2020
8.3. Trend Analysis and Forecast of Current and Future Market Size (USD Million) by Product, 2021-2031
8.3.1. Opioids Acetaminophen
8.3.2. Anesthetics Acetaminophen
8.3.3. Other acetaminophen
8.4. Analysis of market attractiveness by product

9. Global Acetaminophen Market Analysis 2016-2020 and Forecast 2021-2031, by Sales Type
9.1. Introduction/Key Findings
9.2. Trend Analysis of Historic Market Size (USD Million) by Sales Type, 2016-2020
9.3. Trend Analysis and Forecast of Current and Future Market Size (USD Million) by Sales Type, 2021-2031
9.3.1. Prescription (Rx)
9.3.2. Over the counter (OTC)
9.4. Analysis of market attractiveness by type of sale

10. Global Acetaminophen Market Analysis 2016-2020 and Forecast 2021-2031, By Administration
10.1. Introduction/Key Findings
10.2. Trend Analysis of Historic Market Size (USD Million) by Administration, 2016-2020
10.3. Current and Future Market Size Trend Analysis and Forecast (USD Million) By Administration, 2021-2031
10.3.1. Oral
10.3.2. Injectable
10.3.3. others
10.4. Analysis of market attractiveness by route of administration

11. Global Acetaminophen Market Analysis 2016-2020 and Forecast 2021-2031, By Distribution Channel
11.1. Introduction/Key Findings
11.2. Trend Analysis of Historic Market Size (USD Million) by Distribution Channel, 2016-2020
11.3. Trend Analysis and Forecast of Current and Future Market Size (USD Million) by Distribution Channel, 2021-2031
11.3.1. Hospital pharmacies
11.3.2. Retail pharmacies
11.3.3. Pharmacies
11.3.4. E-commerce
11.3.5. Others
11.4. Analysis of market attractiveness by distribution channel

12. Global Acetaminophen Market Analysis 2016-2020 and Forecast 2021-2031, by Region
12.1. Introduction/Key Findings
12.2. Historical Market Size Analysis (USD Million) by Region, 2016-2020
12.3. Current and Future Market Size Analysis and Forecast (USD Million) by Region, 2021-2031
12.3.1. North America
12.3.2. Latin America
12.3.3. Europe
12.3.4. South Asia
12.3.5. East Asia
12.3.6. Oceania
12.3.7. Middle East and Africa
12.4. Market attractiveness analysis by region

13. North America Paracetamol Market Analysis 2016-2020 and Forecast 2021-2031

14. Latin America Acetaminophen Market Analysis 2016-2020 and Forecast 2021-2031

15. Europe Acetaminophen Market Analysis 2016-2020 and Forecast 2021-2031

16. South Asia Acetaminophen Market Analysis 2016-2020 and Forecast 2021-2031

17. East Asia Acetaminophen Market Analysis 2016-2020 and Forecast 2021-2031

18. Oceania Acetaminophen Market Analysis 2016-2020 and Forecast 2021-2031

19. Middle East & Africa Paracetamol Market Analysis 2016-2020 and Forecast 2021-2031

20. Country Level Analysis, Acetaminophen Market Forecast 2021-2031

21. Competitive Analysis
21.1. Contest Dashboard
21.2. Deep competition
21.2.1. Pfizer Inc.
21.2.1.1. Insight
21.2.1.2. Service portfolio
21.2.1.3. Profitability by market segments (product/channel/region)
21.2.1.4. Sales Footprint
21.2.1.5. Strategy overview
21.2.1.5.1. Marketing Strategy
21.2.1.5.2. Service Strategy
21.2.1.5.3. Channel Strategy
21.2.2. Sanofi
21.2.2.1. Insight
21.2.2.2. Service portfolio
21.2.2.3. Profitability by market segments (product/channel/region)
21.2.2.4. Sales Footprint
21.2.2.5. Strategy overview
21.2.2.5.1. Marketing Strategy
21.2.2.5.2. Service Strategy
21.2.2.5.3. Channel Strategy
21.2.3. Janssen Pharmaceuticals.
21.2.3.1. Insight
21.2.3.2. Service portfolio
21.2.3.3. Profitability by market segments (product/channel/region)
21.2.3.4. Sales Footprint
21.2.3.5. Strategy Overview
21.2.3.5.1. Marketing Strategy
21.2.3.5.2. Service strategy
21.2.3.5.3. Channel Strategy
21.2.4. Bayer AG
21.2.4.1. Insight
21.2.4.2. Service portfolio
21.2.4.3. Profitability by market segments (product/channel/region)
21.2.4.4. Sales Footprint
21.2.4.5. Strategy overview
21.2.4.5.1. Marketing Strategy
21.2.4.5.2. Service strategy
21.2.4.5.3. Channel strategy
21.2.5. GlaxoSmithKline plc
21.2.5.1. Insight
21.2.5.2. Service portfolio
21.2.5.3. Profitability by market segments (product/channel/region)
21.2.5.4. Sales Footprint
21.2.5.5. Strategy overview
21.2.5.5.1. Marketing strategy
21.2.5.5.2. Service strategy
21.2.5.5.3. Channel strategy
21.2.6. Bristol-Myers Squibb and Company
21.2.6.1. Insight
21.2.6.2. Service portfolio
21.2.6.3. Profitability by market segments (product/channel/region)
21.2.6.4. Sales Footprint
21.2.6.5. Strategy Overview
21.2.6.5.1. Marketing Strategy
21.2.6.5.2. Service strategy
21.2.6.5.3. Channel Strategy
21.2.7. Teva Pharmaceutical Industries Ltd
21.2.7.1. Insight
21.2.7.2. Service portfolio
21.2.7.3. Profitability by market segments (product/channel/region)
21.2.7.4. Sales Footprint
21.2.7.5. Strategy overview
21.2.7.5.1. Marketing Strategy
21.2.7.5.2. Service strategy
21.2.7.5.3. Channel strategy
21.2.8. Cardinal Health Inc.
21.2.8.1. Insight
21.2.8.2. Service portfolio
21.2.8.3. Profitability by market segments (product/channel/region)
21.2.8.4. Sales Footprint
21.2.8.5. Strategy overview
21.2.8.5.1. Marketing strategy
21.2.8.5.2. Service strategy
21.2.8.5.3. Channel strategy
21.2.9. Perrigo Company.
21.2.9.1. Insight
21.2.9.2. Service portfolio
21.2.9.3. Profitability by market segments (product/channel/region)
21.2.9.4. Sales Footprint
21.2.9.5. Strategy overview
21.2.9.5.1. Marketing strategy
21.2.9.5.2. Service strategy
21.2.9.5.3. Channel strategy
21.2.10. Novartis AG
21.2.10.1. Insight
21.2.10.2. Service portfolio
21.2.10.3. Profitability by market segments (product/channel/region)
21.2.10.4. Sales Footprint
21.2.10.5. Strategy overview
21.2.10.5.1. Marketing strategy
21.2.10.5.2. Service strategy
21.2.10.5.3. Channel strategy
21.2.11. Sun Pharmaceutical Industries Ltd
21.2.11.1. Insight
21.2.11.2. Service portfolio
21.2.11.3. Profitability by market segments (product/channel/region)
21.2.11.4. Sales Footprint
21.2.11.5. Strategy overview
21.2.11.5.1. Marketing strategy
21.2.11.5.2. Service Strategy
21.2.11.5.3. Channel Strategy
21.2.12. Abbott
21.2.12.1. Insight
21.2.12.2. Service portfolio
21.2.12.3. Profitability by market segments (product/channel/region)
21.2.12.4. Sales Footprint
21.2.12.5. Strategy Overview
21.2.12.5.1. Marketing Strategy
21.2.12.5.2. Service strategy
21.2.12.5.3. Channel Strategy
21.2.13. Mallinckrodt Pharmaceuticals
21.2.13.1. Insight
21.2.13.2. Service portfolio
21.2.13.3. Profitability by market segments (product/channel/region)
21.2.13.4. Sales Footprint
21.2.13.5. Strategy overview
21.2.13.5.1. Marketing Strategy
21.2.13.5.2. Service Strategy
21.2.13.5.3. Channel Strategy
21.2.14. Procter & Gamble Company
21.2.14.1. Insight
21.2.14.2. Service portfolio
21.2.14.3. Profitability by market segments (product/channel/region)
21.2.14.4. Sales Footprint
21.2.14.5. Strategy overview
21.2.14.5.1. Marketing strategy
21.2.14.5.2. Service Strategy
21.2.14.5.3. Channel Strategy

22. Assumptions and acronyms used

23. Research Methodology

For more information on this report, visit https://www.researchandmarkets.com/r/mgb94d

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900


Source link

Comments are closed.